SEC Comment Letter for Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS) — Nov 16, 2021
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Nov. 16, 2021 · CIK: 0001447028 · Accession: 0000000000-21-013816
AI Filing Summary & Sentiment
File numbers found in text: 333-260782
Letter
United States securities and exchange commission logo November 16, 2021 William H. Collier President and Chief Executive Officer Arbutus Biopharma Corporation 701 Veterans Circle Warminster, Pennsylvania 18974 Re:Arbutus Biopharma Corporation Registration Statement on Form S-3 Filed November 4, 2021 File No. 333-260782 Dear Mr. Collier: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen M. Nicolai, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2021
William H. Collier
President and Chief Executive Officer
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, Pennsylvania 18974
Re:Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 4, 2021
File No. 333-260782
Dear Mr. Collier:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Davis at 202-551-4385 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephen M. Nicolai, Esq.